FWIW, someone made a very good point yesterday and it

New Post Public Reply Private Reply Replies (1) Message Board
Goodspeed65
FWIW, someone made a very good point yesterday and it should probably be reiterated so those considering understand the implications of hiring the new boss.

Someone or someone(s) where buying last week. There was no news, no catalyst and nothing pending except the anticipated release of Rico; and who knows when that drops? However, people were buying.

Is it fair to think that there were some that were in the know about this impending change and they were aware of the background and credentials of Dr. Jones?

The selling can more than likely be linked to the sexy pick heading out the door with his connections and media attention. Perhaps even some of his students or friends buying in who showed their weak hands once news of RCs departure hit? Knee-jerk reactions from those that really didn't buy for the sector and long-run, but for the name only. Bad investment strategy in my book.

However, many were buying and buying hard. If they knew something was up with this change and knew Jones was heading in and had something to bring to the table that was just as big as what Calkin could bring, like, oh maybe, agricultural, perhaps we'll see substantially improved communication and dedication and the direction we are all hoping for finally come to realization.

I just have a feeling something bigger is in the long range plan and some got wind of what that plan entails. Maybe its just a BS conspiracy theory, but its what I'm banking on.

Green Cures & Botanical Distribution Inc. (GRCU) Stock Research Links

GRCU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Merck & Co., Inc. Investors Urged to Take Action Now

Updated Category News Views 131

Important Notice for Merck & Co., Inc. Investors Investors in Merck & Co., Inc. (MRK) are being encouraged to seek legal counsel as we approach a significant deadline related to a securities class action lawsuit. This timeline marks an important opportunity for purchasers of Merck's securities made between February 3, 2022, and February 3, 2025, to secure representation...

Continue Reading
Justice-Impacted Individuals Gaining Access to Education

Updated Category News Views 116

Expanding Opportunities for Justice-Impacted Individuals In a significant initiative aimed at improving the lives of justice-impacted individuals, multiple states are coming together to enhance educational and workforce pathways. This collaborative effort is focused on providing necessary resources and opportunities for individuals who have faced incarceration, aiming to...

Continue Reading
Celebrating Excellence: 2025 Lifetime Achievement Award Recipients

Updated Category News Views 123

Honoring Peter Murray and SawTeen See at the CTBUH 2025 Awards The Council on Tall Buildings and Urban Habitat (CTBUH) has recognized two remarkable figures in the field of architecture and structural engineering for their essential contributions to urban design. Peter Murray, co-founder of New London Architecture, and SawTeen See, a prominent structural engineer, are the...

Continue Reading
Northern Oil and Gas Expands Horizons with Acquisition Talks

Updated Category News Views 145

Northern Oil and Gas Options for Strategic Growth Northern Oil and Gas is actively pursuing acquisition opportunities, specifically targeting Granite Ridge Resources. Based in Minneapolis, this ambitious company has shown intent to enhance its portfolio by considering Granite Ridge, a relatively smaller player in the oil industry, skilled in extracting resources from...

Continue Reading
Invivyd Announces Insights into VYD2311's Clinical Journey

Updated Category News Views 176

Invivyd Hosts Webcast to Discuss the REVOLUTION Program Invivyd, Inc. (Nasdaq: IVVD) will present a live webcast detailing its innovative REVOLUTION clinical program. This event, aimed at both investors and the public, will showcase the company’s promising monoclonal antibody, VYD2311, which serves as a vaccine alternative for COVID-19 prevention. The Overview of...

Continue Reading